Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

CPV: Health services

Procedure method

Open procedure

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Services

Notice status

Awarded

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Competitive procedure

GPA / WTO covered

Yes (GPA)

Recurring procurement

Yes

First published

4 Jun 2026, 16:37 BST

Last source update

22 Sept 2026, 16:39 BST

Award evaluation window

8 Jul 2026 – …

Authority reference

C449537

FTS notice number

2026/S 000-089823

Classification (CPV)

Health services

Delivery area

UK

Official registry OCID

ocds-h6vhtk-06ae08 Find a Tender

Publisher note: Spinal muscular atrophy (SMA) is a rare genetic disorder that causes muscle weakness and progressive loss of movement. The severity of SMA can vary greatly between individuals. Historically, the condition has been classified into different types, determined by clinicians at the time of diagnosis. This classification is based on both the age at which symptoms first appear, and the highest level of motor function achieved by the patient.<br/><br/>The types range from type 0, the most severe form, where symptoms are present before birth and most affected infants do not survive past 6 months, through to type 4, which develops in adulthood and is associated with mild motor impairment and a normal life span. However, because the disease presents so variably, consistently categorising patients into these types at the point of diagnosis can be challenging.<br/><br/>Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.<br/><br/>This award is based on Lots with the intention to cover the population served by NHS England.<br/><br/>Lots:<br/>Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)<br/><br/>Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)<br/><br/>Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)<br/><br/>This is a Provider Selection Regime (PSR) intention to award notice. The awarding of these contracts is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice.<br/><br/>Representations by providers must be made to the relevant authority by Friday 02 October 2026. These contracts have not yet formally been awarded; this notice serves as an intention to award under the PSR. Representations should be sent to [email protected].<br/><br/>The award decision‑makers were NHS England’s National Commissioning Group (NCG).<br/><br/>The rationale for selecting the provider(s) was based on them meeting all mandatory requirements and achieving the minimum quality threshold set out in the procurement documentation. This decision has been made as per NHS England governance processes, by the National Commissioning Group on 12th September 2025. No conflicts of Interest were identified amongst decision-makers.<br/> <br/>The Key Criteria used for the award:<br/>Lot 1 Quality: 90%<br/>Lot 1 Social Value 10%<br/>Lot 2 Quality: 90%<br/>Lot 2 Social Value 10%<br/>Lot 3 Quality: 90%<br/>Lot 3 Social Value 10%

Submission deadline

8 Jul 2026, 12:00 BST

Submission channel

{"electronicSubmission","written"}

Accepted languages

en

Bid validity

180 days from the deadline

Bids opened

8 Jul 2026, 13:00 BST

21 further award records carry no date or value.

• AlderHey Children's NHS FTAwarded supplier00000N/A Eaton Road, Liverpool, UK, L12 2AP
• Great Ormond Street HospitalAwarded supplier London, UK
• Guy's and St Thomas' NHS Foundation TrustAwarded supplier00000N/A Great Maze Pond. London, London, Wales, SE1 9RT
• KING'S COLLEGE HOSPITAL NHS FTAwarded supplier00000N/A Denmark Hill LONDON, London, UK, SE5 9RS
• Leeds Teaching Hopsital NHS Foundation TrustAwarded supplier Trust HQ at St James's University Hospital, Beckett Street, Leeds,, Leeds, UK, LS9 7TFContact phoneShow contact details
• North Manchester General HospitalAwarded supplier00000N/A Delaunays Rd Crumpsall Manchester, Manchester, UK, M8 5RBContact phoneShow contact details
• Northern Care Alliance NHS Foundation TrustAwarded supplier00000N/A SALFORD ROYAL STOTT LANE SALFORD GREATER MANCHESTER, Salford, UK, M6 8HDContact email, phoneShow contact details
• Oxford University Hospitals NHS FTAwarded supplier00000N/A John Radcliffe Hospital Headley Way Headington Oxford, Oxford, UK, OX3 9DU
• Sheffield Children's NHS Foundation TrustAwarded supplierCRN: N/A - 927664 Sheffield Children's Hospital Western Bank, Sheffield, UK, S10 2THContact phoneShow contact details
• Sheffield Teaching Hospitals NHS Foundation TrustAwarded supplier00000RHQ Northern General Hospital Herries Road Sheffield South Yorkshire S5 7AU UK, Sheffield, Yorkshire & Humber, S5 7AUContact email, phoneShow contact details

No document links were published on the notice.